Matching articles for "aspariginase Erwinia chrysanthemi"
In Brief: Asparaginase Erwinia chrysanthemi (Erwinaze) for ALL
The FDA has approved asparaginase Erwinia chrysanthemi ( Erwinaze – EUSA), an asparagine-specific enzyme derived from the gram-negative bacillus Erwinia chrysanthemi , for use in combination with other…
Med Lett Drugs Ther. 2012 Apr 16; 54(1388):32
The FDA has approved asparaginase Erwinia chrysanthemi ( Erwinaze – EUSA), an asparagine-specific enzyme derived from the gram-negative bacillus Erwinia chrysanthemi , for use in combination with other chemotherapeutic agents for treatment of acute lymphoblastic leukemia (ALL) in patients who have had allergic reactions to Escherichia coli -derived asparaginase ( Elspar or pegaspargase [Oncaspar] ). ALL is the most common malignancy of childhood. Multidrug chemotherapy can cure about 80% of children with ALL. 1 Initial treatment ("induction") usually includes vincristine, a glucocorticoid, and an asparaginase and/or an anthracycline. Inclusion of an asparaginase in ALL regimens improves outcomes, especially in pediatric patients, but approximately 15-20% of patients treated with E. coli -derived asparaginase will develop hypersensitivity to the drug. In one study, 42 E. coli asparaginase-allergic children with ALL were switched to twice-weekly Erwinia asparaginase 25,000 IU/m 2 to complete 30 weeks of asparaginase treatment; 81% of patients completed ≥26 weeks of therapy. At a median follow-up of 5.4 years, event-free survival in those children was similar to that of children without E. coli asparaginase allergy (86% vs. 81%). Allergy to Erwinia asparaginase developed in 33% of patients. 2 1. CH Pui and WE Evans. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166. 2. LM Vrooman et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54:199. Download complete U.S. English article
